Scorpius Holdings Set to Launch First Mammalian cGMP Campaign at San Antonio Facility in the 2024 3rd Quarter
Scorpius Holdings (NYSE American: SCPX) has announced plans to launch its first cGMP mammalian manufacturing campaign at its San Antonio facility in Q3 2024. This milestone expands the company's biomanufacturing capabilities, particularly in mammalian cell culture production for advanced biopharmaceuticals. The launch follows the initiation of cGMP activities in Scorpius' microbial facilities, opening additional revenue streams for its CDMO operations.
CEO Jeff Wolf highlighted the rapid progress, noting that the mammalian facilities became operational in less than two years. The company's focus is on providing personalized attention and flexibility to clients, with cleanrooms featuring mobile equipment for customized configurations. Scorpius has already secured bookings for additional cGMP activities in the mammalian building for 2025, indicating strong demand for its expanded capabilities.
Scorpius Holdings (NYSE American: SCPX) ha annunciato l'intenzione di lanciare la sua prima campagna di produzione cGMP per mammiferi presso il suo stabilimento di San Antonio nel terzo trimestre del 2024. Questo traguardo amplia le capacità di biomanifattura dell'azienda, in particolare nella produzione di colture cellulari di mammiferi per biopharmaceuticals avanzati. Il lancio segue l'avvio delle attività cGMP nelle strutture microbiche di Scorpius, aprendo ulteriori flussi di entrate per le sue operazioni CDMO.
Il CEO Jeff Wolf ha sottolineato il rapido progresso, notando che le strutture per mammiferi sono diventate operative in meno di due anni. L'azienda si concentra sulla fornitura di attenzione personalizzata e flessibilità ai clienti, con camere bianche dotate di attrezzature mobili per configurazioni personalizzate. Scorpius ha già assicurato prenotazioni per ulteriori attività cGMP nell'edificio per mammiferi per il 2025, indicando una forte domanda per le sue capacità ampliate.
Scorpius Holdings (NYSE American: SCPX) ha anunciado planes para lanzar su primera campaña de fabricación cGMP para mamíferos en su instalación de San Antonio en el tercer trimestre de 2024. Este hito amplía las capacidades de biomanufactura de la empresa, especialmente en la producción de cultivos celulares de mamíferos para productos biofarmacéuticos avanzados. El lanzamiento sigue a la iniciación de actividades cGMP en las instalaciones microbianas de Scorpius, abriendo nuevas fuentes de ingresos para sus operaciones CDMO.
El CEO Jeff Wolf destacó el rápido progreso, señalando que las instalaciones para mamíferos se volvieron operativas en menos de dos años. La empresa se centra en proporcionar atención personalizada y flexibilidad a los clientes, con salas limpias que cuentan con equipos móviles para configuraciones personalizadas. Scorpius ya ha asegurado reservas para actividades cGMP adicionales en el edificio para mamíferos para 2025, lo que indica una fuerte demanda por sus capacidades ampliadas.
Scorpius Holdings (NYSE American: SCPX)는 2024년 3분기 텍사스 샌안토니오 시설에서 첫 번째 cGMP 포유류 제조 캠페인을 시작할 계획을 발표했습니다. 이 이정표는 특히 고급 생물제약을 위한 포유류 세포 배양 생산에 있어 회사의 생물 제조 능력을 확장합니다. 이번 출시는 Scorpius의 미생물 시설에서 cGMP 활동이 시작된 후 이루어지며, CDMO 운영을 위한 추가 수익원을 개척합니다.
CEO 제프 울프는 포유류 시설이 두 년도 채 안 되어 운영을 시작했다며 빠른 발전을 강조했습니다. 회사는 고객에게 개인화된 주의와 유연성을 제공하는 데 초점을 맞추고 있으며, 맞춤형 구성을 위한 이동식 장비가 갖춰진 청정실을 운영합니다. Scorpius는 이미 2025년 포유류 건물에서의 추가 cGMP 활동에 대한 예약을 확보했으며, 이는 확장된 능력에 대한 강한 수요를 나타냅니다.
Scorpius Holdings (NYSE American: SCPX) a annoncé des plans pour lancer sa première campagne de fabrication cGMP pour mammifères dans son établissement de San Antonio au troisième trimestre 2024. Ce jalon élargit les capacités de biomanufacturation de l'entreprise, en particulier dans la production de cultures cellulaires de mammifères pour des biopharmaceutiques avancés. Le lancement fait suite à l'initiation d'activités cGMP dans les installations microbiennes de Scorpius, ouvrant de nouveaux flux de revenus pour ses opérations CDMO.
Le PDG Jeff Wolf a souligné les progrès rapides, notant que les installations pour mammifères sont devenues opérationnelles en moins de deux ans. L'entreprise se concentre sur la fourniture d'une attention personnalisée et de la flexibilité aux clients, avec des salles blanches équipées d'équipements mobiles pour des configurations personnalisées. Scorpius a déjà sécurisé des réservations pour des activités cGMP supplémentaires dans le bâtiment pour mammifères pour 2025, ce qui indique une forte demande pour ses capacités élargies.
Scorpius Holdings (NYSE American: SCPX) hat Pläne angekündigt, im dritten Quartal 2024 seine erste cGMP-Mammiferen-Herstellungskampagne in seiner Einrichtung in San Antonio zu starten. Dieser Meilenstein erweitert die biomanufacturing Fähigkeiten des Unternehmens, insbesondere in der Produktion von Zellkultur für fortgeschrittene Biopharmazeutika. Der Start folgt der Initiierung von cGMP-Aktivitäten in den mikrobielle Einrichtungen von Scorpius, was zusätzliche Einnahmequellen für seine CDMO-Operationen erschließt.
CEO Jeff Wolf hob den schnellen Fortschritt hervor und merkte an, dass die Mammiferenanlagen in weniger als zwei Jahren betriebsbereit wurden. Das Unternehmen konzentriert sich darauf, den Kunden persönliche Betreuung und Flexibilität zu bieten, mit Reinräumen, die über mobile Geräte für maßgeschneiderte Konfigurationen verfügen. Scorpius hat bereits Buchungen für zusätzliche cGMP-Aktivitäten im Mammiferengebäude für 2025 gesichert, was auf eine starke Nachfrage nach den erweiterten Fähigkeiten hinweist.
- Expansion into mammalian cGMP manufacturing, opening new revenue streams
- Rapid operational readiness of mammalian facilities in less than two years
- Secured bookings for additional cGMP activities in 2025, indicating future demand
- None.
Launching the first cGMP mammalian manufacturing campaign is a strategic move for Scorpius Holdings, expanding their revenue streams and establishing them as a key player in the biomanufacturing sector. This development could attract new clients looking for reliable CDMO services, particularly in the rapidly growing biopharmaceutical market. The secured bookings for 2025 indicate strong demand and client confidence, reflecting positively on future revenue projections. Investors should note the potential for scalable growth as Scorpius leverages its new facilities to cater to early-stage clinical programs.
Scorpius Holdings' entry into mammalian cGMP manufacturing is significant given the rising demand for biologics and cell therapies. The company's ability to operationalize a complex buildout ahead of schedule showcases their operational efficiency and market readiness. The flexibility and customization of their cleanrooms cater to a diverse client base, which is a competitive advantage. This move positions Scorpius well in a market expected to see substantial growth, thereby potentially increasing market share and fostering long-term client relationships.
The addition of mammalian cGMP manufacturing capabilities at Scorpius Holdings is a noteworthy milestone in the biopharmaceutical industry. It allows for the production of more complex biologics, which are important for advanced therapies. The rapid setup and operational efficiency highlight the company's robust project management and technical expertise. This development supports the advancement of early-stage clinical programs, which are critical for innovation in biopharmaceuticals. Investors can see this as a positive sign of Scorpius' commitment to advancing healthcare solutions and expanding their service offerings.
DURHAM, N.C., July 24, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced that the Company expects to launch its first cGMP mammalian manufacturing campaign at its San Antonio manufacturing facility in the 3rd quarter of 2024. This milestone highlights the expansion of the Company’s biomanufacturing capabilities, particularly in the field of mammalian cell culture production for advanced biopharmaceuticals.
Scorpius has previously initiated cGMP activities in its microbial facilities, and the commencement of mammalian cGMP campaigns marks a significant development as it opens additional revenue streams for the Company’s CDMO operations. Scorpius boasts a dedicated mammalian cell culture facility with cGMP-compliant controlled cleanrooms illustrating Scorpius' commitment to providing tailored and adaptable manufacturing solutions.
Jeff Wolf, CEO of Scorpius, remarked, “I am extremely proud of what our team has accomplished in a short period of time. Our manufacturing and quality teams have worked exceptionally hard to get our mammalian facilities operational in less than two years, well ahead of the typical timing for such complex buildouts. Scorpius is now extremely well-positioned to support a wide range of early-stage clinical programs."
“Our focus at Scorpius is providing each client the personalized attention and systematic flexibility they deserve. Our facility's design includes cleanrooms with mobile equipment, allowing for easily customized configurations to meet the specific needs of each project. Our strategy is to expand our scope of services as our clients advance their respective programs through clinical development. Looking ahead, Scorpius has already secured bookings for additional cGMP activities in the mammalian building for 2025, demonstrating the demand and confidence in our expanded capabilities,” concluded Mr. Wolf.
Scorpius Holdings, Inc.
Scorpius Holdings Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as launching Scorpius’ first cGMP mammalian manufacturing campaign at its San Antonio manufacturing facility in the 3rd quarter of 2024, opening additional revenue streams for Scorpius’ operations, being extremely well-positioned to support a wide range of early-stage clinical programs, expanding the scope of services as Scorpius’ clients advance their respective programs through clinical development. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to launch its first cGMP mammalian manufacturing campaign and open additional revenue streams as planned; expand its large molecule biomanufacturing CDMO services and continue to grow revenue; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
ir@scorpiusbiologics.com
FAQ
When will Scorpius Holdings (SCPX) launch its first cGMP mammalian manufacturing campaign?
What new capabilities does the mammalian cGMP campaign bring to Scorpius Holdings (SCPX)?
Has Scorpius Holdings (SCPX) secured any future bookings for its mammalian cGMP facilities?
